ClinicalTrials.gg
CompletedNCT04337970Updated Oct 6, 2026Results posted

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

A Phase 1/2 interventional study of Talazoparib and Axitinib in Kidney Cancer, Renal Cell Carcinoma and Unresectable Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Primary conditionCarcinoma, Renal CellRegistry: Kidney NeoplasmsReclassifiedWhy we changed it
Registry
Kidney Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Renal Cell
Why
  1. The study's listed conditions name Carcinoma, Renal Cell, a narrower term within Kidney Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 6, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.

Enrollment
28th of 41
23 · median 40
Started
2020
with 1 other
Phase 1/2
2 of 41
none open now
Registered
22nd of 41
by date

Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 28th largest by enrollment, is one of 2 that started in 2020, is one of 2 in phase 1/2, and was the 22nd registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About axitinib

Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing axitinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Researchers are doing this study to find out if the combination of the drugs axitinib and talazoparib is a safe and effective treatment for people with your previously treated advanced kidney cancer. Researchers will look for the highest dose of talazoparib that causes few or mild side effects when given in combination with a standard dose of axitinib.

03

Conditions studied

  • Kidney Cancer
  • Renal Cell Carcinoma
  • Unresectable Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma

Browse trials for

Keywords

  • Kidney Cancer
  • Advanced Kidney Cancer
  • Renal Cell Carcinoma
  • Unresectable Renal Cell Carcinoma
  • Talazoparib
  • Axitinib
  • Metastatic Renal Cell Carcinoma
  • 20-001
  • Memorial Sloan Kettering Cancer Center
04

In context

Carcinoma, Renal Cell Reclassified

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

This study's enrollment of 23 is below the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.

Browse Carcinoma, Renal Cell studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Compared within Carcinoma, Renal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven or unresectable renal cell carcinoma with clear cell component
  • Prior treatment with at least 1 VEGFR TKI and 1 /PD-L1 immune checkpoint inhibitor (ICI).Combination VEGFR TKI plus ICI will be counted as 1 . During the dose escalation portion of the study prior TKI exposure is not required.
  • Dose escalation portion: No maximum prior lines of therapy. Dose expansion portion: maximum of two prior lines of therapy
  • Adequate Hematologic Function

    • ≥ 1.5 x 109 / L
    • Count ≥ 100 x 10\^9 / L
    • ≥ 9 g/dL
    • No transfusion of packed red blood cells or platelets within 21 days of Cycle 1 Day 1
  • Adequate Renal Function ≥ 60 ml/min according to the formula

    ° Patients with moderate renal impairment (creatinine clearance 30-59 ml/min by Cockcroft-Gault) may be eligible in the phase II dose expansion

  • Adequate Hepatic Function including:

    • Total ≤ 1.5 x (ULN)
    • ≤ 3 x upper limit of normal (ULN) without liver metastasis
    • ALT ≤ 3 x upper limit of normal (ULN) without liver metastasis
    • AST or ALT ≤ 5 x upper limit of normal (ULN) for patients with liver metastasis
    • Patients with known Gilbert's syndrome may be included if total bilirubin ≤ x 3 ULN
  • Eastern Cooperative Group () Performance Status 0-2.
  • Patients must have by v1.1. At least one measurable lesion should not have been previously irradiated.
  • Women of must have negative urine or serum pregnancy testing at screening. All women will be considered childbearing potential unless meeting criteria including:

    • Achieved status as defined by cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have follicular stimulation hormone showing postmenopausal state. Women who have been amenorrhoeic for ≥ 12 months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anorexia, low body weight, ovarian suppression, anti-estrogen therapy or other medically inducible reasons.
    • Documented hysterectomy or bilateral oophorectomy surgery
    • Medically confirmed ovarian failure
    • Sexually active participants and their partners must agree to use medically accepted methods of (i.e. barrier methods including condoms, female condom, or diaphragm with spermicidal gel) during the study and for 7 months after the last dose of the study treatment for women, and 4 months for men.
  • Recovery of baseline v5.0 grade ≤1 toxicities related to prior study treatments unless adverse events are clinically non-significant per investigator's discretion and/or stable on supportive therapy if needed.
  • Patients must be willing and able to comply with trial protocol. This includes adhering to the treatment plan, scheduled visits, laboratory and other study procedures.

Participant Inclusion Criteria for Phase II Dose Expansion

  • Maximum 2 lines of prior therapy. Combination VEGFR TKI plus ICI therapy will be accepted as 1 line of therapy.
  • Adequate Renal Function ≥ 30 ml/min according to the Cockcroft-Gault formula.

    • Patients with normal renal function (Cr clearance ≥ 60 ml/min by Cockcroft-Gault formula) will receive talazoparib at RP2D.
    • Patients with moderate renal impairment (Cr clearance 30-59 ml/min by Cockcroft-Gault formula) will receive talazoparib at one dose level lower than RP2D.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with talazoparib or other agents which target PARP
  • Prior treatment with axitinib. Other VEGFR TKIs are permissible.
  • Patients \< 18 years old
  • Patients who are pregnant or breast-feeding. Fertile patients who are unwilling or unable to use two methods of (at least one of which considered highly effective) for duration of study and after study (7 months after last dose of the study treatment for women, and 4 months for men)
  • Prior diagnosis of myelodysplastic syndrome (MDS) or diagnosis of other that requires anti-cancer directed therapy within the last 12 months. Exclusions include those cancers that are considered cured by local therapy (e.g. basal cell carcinoma, squamous cell carcinoma, ducal carcinoma in situ of breast, bladder of cervix) or other cancers that have low malignant potential and do not require systemic therapy (i.e. Gleason-grade \<6 prostate adenocarcinoma, borderline ovarian malignancy / low malignant potential).
  • Treatment with anti-cancer therapies within 21 days or five half-lives, whichever shorter, of start date, including monoclonal antibody, cytotoxic therapy, or another agent.
  • Significant vascular disease (i.e. aortic aneurysm requiring surgical repair, recent arterial thrombosis) within 6 months prior to first dose of therapy.
  • (EF) ≤50% by echocardiogram (ECHO). Multi-gated acquisition scan (MUGA) should be obtained to estimate EF if quality of ECHO is insufficient.
  • Uncontrolled hypertension defined as systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥ 100 mmHg despite anti-HTN therapy.
  • Evidence of bleeding diathesis or significant unexplained coagulopathy (i.e. absent of anticoagulation)
  • Clinical signs or symptoms of gastrointestinal obstruction requirement parenteral hydration, parenteral nutrition, or feeding tube.
  • Uncontrolled effusion management (pleural effusion, pericardial effusion, or ascites) which requires recurrent drainage procedures.
  • Active infection requiring parenteral antibiotic therapy.
  • History of either positive viral load or anti-HCV antibody screening detectable; infection with HBV surface antigen detection and/or positive HBV DNA viral load.
  • Known to talazoparib or axitinib, or any component in formulations.
  • Severe acute or chronic medical conditions which may significantly increase the risk of study participants, per treating investigator's discretion.
  • Radiation therapy to any site (including bone) \<2 weeks prior to the first dose of therapy
  • Symptomatic or requiring use. Patients are eligible if they are neurologically stable for 4 weeks, have completed radiation therapy or surgery, and recovered from side effects. Patients must have discontinued steroid therapy for at least 2 weeks prior to first dose of study treatment.
  • Current or anticipated use of potent P-gp inhibitors within 7 days prior to randomization or anticipated use during the study
  • Inability to swallow capsules, known intolerance to talazoparib and axitinib or its , known malabsorption syndrome, or other conditions which impair intestinal absorption.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Phase Ib, Dose Level 1

    3-6 participants

    Drug: Talazoparib · Drug: Axitinib

  • Experimental
    Phase Ib, Dose Level 2

    3-6 participants

    Drug: Talazoparib · Drug: Axitinib

  • Experimental
    Phase Ib, Dose Level 3

    3-6 participants

    Drug: Talazoparib · Drug: Axitinib

  • Experimental
    Phase II, Dose Expansion

    Optimal Simon 2-stage Design (14 participants initially, if MTD is tolerated well then accrual will go up to 25 participants)

    Drug: Talazoparib · Drug: Axitinib

Interventions

  • Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily Phase II: MTD to be determined.

  • 5 mg PO BID

07

What researchers measure

Primary outcomes

  1. Phase Ib: Recommended Dose of Talazoparib in Combination With Standard-dose Axitinib

    Identify the recommended Phase II dose of talazoparib in combination with standard-dose axitinib

    Time frame: up to 2 years

  2. Phase Ib: Number of Dose Limiting Toxicity

    Dose-limiting toxicity based on adverse events classified according to CTCAE v5.0 observed over 1 cycle of combination talazoparib and axitinib.

    Time frame: 28 days

  3. Phase II: Objective Response Rate

    Evaluate the efficacy as measured by objective response rate (ORR) of combination talazoparib and axitinib in previously treated metastatic clear cell RCC patients.

    Time frame: 2 years

08

Results

Posted Oct 6, 2026

Participant flow

Participant flow — Overall Study
MilestonePhase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose Expansion
Started3668
Completed0000
Not completed3668
Withdrew: Disease progression3667
Withdrew: Adverse event0001

Outcome measures

PrimaryPhase Ib: Recommended Dose of Talazoparib in Combination With Standard-dose Axitinib

Identify the recommended Phase II dose of talazoparib in combination with standard-dose axitinib

Time frame:
up to 2 years
Reported as:
Number · mg
Phase Ib: Recommended Dose of Talazoparib in Combination With Standard-dose Axitinib
mgPhase Ib
Phase Ib: Recommended Dose of Talazoparib in Combination With Standard-dose Axitinib1.0
PrimaryPhase Ib: Number of Dose Limiting Toxicity

Dose-limiting toxicity based on adverse events classified according to CTCAE v5.0 observed over 1 cycle of combination talazoparib and axitinib.

Time frame:
28 days
Reported as:
Number · number of DLTs
Phase Ib: Number of Dose Limiting Toxicity
number of DLTsPhase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose Expansion
Phase Ib: Number of Dose Limiting Toxicity011NA
PrimaryPhase II: Objective Response Rate

Evaluate the efficacy as measured by objective response rate (ORR) of combination talazoparib and axitinib in previously treated metastatic clear cell RCC patients.

Time frame:
2 years
Reported as:
Count of participants · Participants
Phase II: Objective Response Rate
ParticipantsPhase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose Expansion
Participants with ORR———7
Participants without ORR———1

Adverse events

Collected over 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase Ib, Dose Level 12/3 (66.7%)1/3 (33.3%)3/3 (100%)
Phase Ib, Dose Level 25/6 (83.3%)1/6 (16.7%)6/6 (100%)
Phase Ib, Dose Level 33/6 (50%)4/6 (66.7%)6/6 (100%)
Phase II, Dose Expansion1/8 (12.5%)2/8 (25%)8/8 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPhase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose Expansion
planned tumor resectionInjury, poisoning and procedural complications1/30/60/60/8
Right hip stabilizationMusculoskeletal and connective tissue disorders1/30/60/60/8
Spinal cord compressionNervous system disorders1/30/60/60/8
Abdominal painGastrointestinal disorders0/30/61/61/8
Alkaline phosphatase increasedInvestigations0/31/60/60/8
AnemiaBlood and lymphatic system disorders0/30/61/60/8
ConfusionPsychiatric disorders0/30/61/60/8
DyspneaRespiratory, thoracic and mediastinal disorders0/30/61/60/8
Extrapyramidal DisorderNervous system disorders0/30/61/60/8
HyponatremiaMetabolism and nutrition disorders0/30/61/60/8
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPhase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose Expansion
AnorexiaMetabolism and nutrition disorders3/34/63/61/8
ArthralgiaMusculoskeletal and connective tissue disorders3/30/62/60/8
Back painMusculoskeletal and connective tissue disorders3/31/60/62/8
ConstipationGastrointestinal disorders3/34/64/62/8
Decrease in platelet countBlood and lymphatic system disorders0/35/61/68/8
DiarrheaGastrointestinal disorders3/36/66/68/8
Dry mouthGastrointestinal disorders3/32/62/60/8
Dry skinSkin and subcutaneous tissue disorders3/31/60/60/8
DyspneaRespiratory, thoracic and mediastinal disorders2/34/66/62/8
FatigueGeneral disorders3/36/66/66/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose ExpansionTotal
Mean49 (44 to 52)59.5 (49 to 69)58.5 (46 to 69)68.5 (56 to 75)61 (44 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Phase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose ExpansionTotal
Female32128
Male045615
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose ExpansionTotal
Hispanic or Latino10517
Not Hispanic or Latino261716
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose ExpansionTotal
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American00011
White256619
More than one race00000
Unknown or Not Reported10012
Region of Enrollment
Region of Enrollment(Participants)Phase Ib, Dose Level 1Phase Ib, Dose Level 2Phase Ib, Dose Level 3Phase II, Dose ExpansionTotal
United States366823
09

Study locations

7 sites
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
  • Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
10

References and documents

Publications

  • Kotecha RR, Doshi SD, Knezevic A, Jacobi R, Woo HJ, Aggen DH, McHugh DJ, Shah NJ, Carlo MI, Keegan NM, Gayadin Y, Chaim J, Donoghue MTA, Iyer G, Lee CH, Feldman DR, Motzer RJ, Voss MH. A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma. Eur Urol Oncol. 2025 Aug;8(4):866-870. doi: 10.1016/j.euo.2025.03.010. Epub 2025 Mar 29. PubMed 40158923 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in May 2025, 61 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

Of 41 non-industry phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 132. This study's 61 months is close to that.

Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2020
First posted
Apr 8, 2020
StartActual
Apr 6, 2020
Primary completionActual
May 23, 2025
CompletionActual
May 23, 2025
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPhase Ib: Recommended doseDose of talazoparibTalazoparib in combination with standardCombination With Standard-dose axitinibAxitinibTime frame: 2 years → up to 2 years
  • EditedPhase Ib: Number of Dose Limiting ToxicityTime frame: 28 days
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPhase Ib: Recommended doseDose of talazoparibTalazoparib in combination with standardCombination With Standard-dose axitinibAxitinibTime frame: 2 years → up to 2 years
    • EditedPhase Ib: Number of Dose Limiting ToxicityTime frame: 28 days
    + 3 other changes: index terms, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT04337970
Responsible party
Sponsor
First posted
Apr 8, 2020
Start date
Apr 6, 2020
Primary completion
May 23, 2025
Completion
May 23, 2025
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Study contacts

Ritesh Kotecha, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Talazoparib · Axitinib

Start the discussion